Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14780962 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL2233593 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL14447399 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL19359634 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL13030308 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL23736061 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL19359635 | 1.00 | EPHX1 (0.50) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL23736062 | 0.97 | SIGMAR1 (0.48) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL16702587 | 0.97 | SIGMAR1 (0.48) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A | |
| SCHEMBL20075957 | 0.97 | SIGMAR1 (0.46) | EPHX1SMN1; SMN2SIGMAR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | EPHX1 2370/4885SMN1; SMN2 3426/4885SIGMAR1 4758/4885 |
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | EPHX1 2370/4885SMN1; SMN2 3426/4885SIGMAR1 4758/4885 |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | EPHX1 2370/4885SMN1; SMN2 3426/4885SIGMAR1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.